Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 22OTHER_GOV 5INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Endostatins × Thoracic × Clear all
NCT04942301 2021-06-30

PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Unknown
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03117335 2017-04-17

Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer

Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.

Phase 3 Completed
560 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡